Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: A possible role of lymphocyte-derived prolactin

Lupus

Volumn 13, Issue 1, 2004, Pages 45-53

  Mendez I ^a   Alcocer Varela, J ^a   Parra, A ^b   Lava Zavala, A ^a   De La Cruz, D A ^a   Alarcon Segovia D ^a   Larrea, Fernando ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

Dopamine; Hyperprolactinemia; Lupus; Prolactin

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; LYMPHOCYTE DERIVED PROLACTIN; METOCLOPRAMIDE; PROLACTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE ACTIVITY; DOPAMINERGIC SYSTEM; FEMALE; GENETIC TRANSCRIPTION; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HYPERPROLACTINEMIA; MOLECULAR WEIGHT; NEUROENDOCRINE SYSTEM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROLACTIN RELEASE; RADIOIMMUNOASSAY; REGULATORY MECHANISM; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; BLOTTING, WESTERN; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; METOCLOPRAMIDE; PROLACTIN; T-LYMPHOCYTES;

EID: 16744362504     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu487oa     Document Type: Article

References (46)

1. Berczi I, Nagy E. Prolactin and other lactogenic hormones. In: Berczi I (ed) Pituitary and Immunity. CRC Press Inc: Boca Raton, FL, 1986, 161-183.
2. Matera L, Mori M, Geuna M, Buttiglieri S, Palestro G. Prolactin in autoimmunity and antitumor defense. J Neuroimmunol 2000; 109: 47-55.
3. Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 1983; 102: 351-357.
4. Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun RE. Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporin. J Immunol 1985; 134: 3027-3031.
5. Matera L, Muccioli G, Cesano A, Bellussi G, Genazzani E. Prolactin receptors on large granular lymphocytes: Dual regulation by cyclosporin A. Brain Behav Immunol 1988; 2: 1-10.
6. Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: An autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992; 89: 7713-7716.
7. Larrea F, Martinez-Castillo A, Cabrera V, Alcocer-Varela J, Queipo G, Cariño C et al. Alarcón-Segovia D. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. J Clin Endocrinol Metab 1997; 82: 3664-3669.
8. Nagy E, Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology 1991; 128: 2776-2784.
9. Matera L. Endocrine, paracrine and autocrine actions of prolactin in immune cells. Life Sci 1996; 59: 599-614.
10. Jara LJ, Gómez-Sánchez C, Silveira LH, Martí nez-Oxuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 303: 222-226.
11. Neidhart M. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996; 23: 476-481.
12. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester G-R, Hiepe E Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001; 10: 554-561.
13. Berwaer M, Martial JA, Davis JRE. Characterisation of an upstream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994; 8: 635-642.
14. Gutiérrez MA, Molina JF, Jara LJ, Cuéllar ML, García C, Gutiérrez-Urefia S et al. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus 1995; 4: 348-352.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the clasification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
16. Guzmán J, Cradiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
17. Larrea F, Sandoval JL, Salinas E, Franco-Rodríguez VA, Méndez I, Ulloa-Aguirre A. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia. Clin Endocrinol (Oxf) 1995; 43: 591-600.
18. Tanaka T, Shiu RPC, Gout PW, Beer CT, Noble RL, Friesen HG. A new sensitive and specific bioassay for lactogenic hormone measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab 1980; 51: 1058-1063.
19. Sinha YN, Gilligan TA, Lee DW. Detection of high molecular weight variant of prolactin in human plasma by a combination of electrophoretic and immunological technics. J Clin Endocrinol Metab 1984; 58: 752-754.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
21. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
22. Maniatis T, Jeffrey A, van der Sande H. Chain length determination of small double and single-stranded DNA molecules by polyacrylamide gel electrophoresis. Biochemistry 1975; 14: 3787-4394.
23. Cooke NE, Coit D, Shine J, Baxter JD, Martial JA. Human prolactin, cDNA structural analysis and evolutionary comparisons. J Biol Chem 1981; 256: 4007-4016.
24. Quigley ME, Judd SJ, Gilliland GB, Yen SSC. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. J Clin Endocrinol Metab 1979; 48: 718-720.
25. Parra A, Barron J, Sinibaldi J, Coria I, Espinosa de los Monteros A. Differences in the metoclopramide-induced prolactin release related to age at first full-term pregnancy or nulliparity. Hum Reprod 1997; 12: 214-219.
26. Parra A, Ramirez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I et al. Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin Endocrinol 2001; 54: 731-738.
27. Zoli A, Ferlisi EM, Pompa A, Barini A, Altomonte L, Mirone L, Magaro M. Basal and after-stimuli test for prolactinemia in systemic lupus erythematosus. Ann NY Acad Sci 1999; 876: 155-158.
28. Takemoto M, Morishita H, Higuchi K, Yoshida J, Aono T. Effects of body weight on responses of serum prolactin to metoclopramide and thyrotropin-releasing hormone in secondary amenorrhoeic women. Hum Reprod 1994; 9: 800-805.
29. Ferreira C, Paes M, Gouveia A, Ferreira E, Pádua F, Fiuza T. Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Lupus 1998; 7: 392-397.
30. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr Rev 1985; 6: 564-589.
31. Candito M, Durant J, Gurle V, Chambon P, Dallamonica P. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in AIDS dementia complex. AIDS 1995; 9: 1100-1101.
32. Blanco-Favela F, Chávez-Rueda K, Leaños-Miranda A. Analysis of anti-prolactin antibodies in systemic lupus erythematosus. Lupus 2001; 10: 757-761.
33. Bucala R, Lahita RG, Fishman J, Cerami A. Increased levels of 16 alpha-hydroxyestrone-modified proteins in pregnancy and in systemic lupus erythematosus. J Clin Endocrinol Metab 1985; 60: 841-847.
34. Jara LJ, Prasad C, Espinoza LR. Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients. Lupus 1997; 6: 258-260.
35. Spangalo BL, Judd AM, Isakson PC, McLeod RM. Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 1989; 125: 575-577.
36. Gutiérrez MA, Anaya JM, Scopelitis E, Citera G, Silveira L, Espinoza LR. Hyperprolactinaemia in primary Sjogren's syndrome. Ann Rheum Dis 1994; 53: 425.
37. El-Graf A, Salah S, Shaarawg M, Zaqui S, Anwer S. Prolactin hormone in juvenile systemic lupus erythematosus: a possible relationship to disease activity and SNC manifestations. J Rheumatol 1996; 23: 374-377.
38. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR. Transcriptional analysis of multiple sclerosis brain lessions reveals a complex pattern of cytokine expression. J Immunol 2000; 165: 6576-6582.
39. Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 199; 26: 1890-1900.
40. Reem GH, Ray DW, Davis JRE. The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and cAMP. J Mol Endocrinol 1999; 22: 285-293.
41. Stevens A, Ray DW, Worthington J, Davis JRE. Polymorphisms of human prolactin gene: implications for production of lymphocyte prolactin in systemic lupus erythematosus. Lupus 2001; 10: 676-683.
42. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for the Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-596.
43. Gellersen B, Kempf R, Telgmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994; 8: 356-373.
44. Matera L, Bellone G, Lebren JJ, Kelly PA, Hooghe-Peters EL, DiCelle PF et al. Role of prolactin in the in vitro development of interleukine-2-driven anti tumoral lymphokine-activated killer cells. Immunology 1996; 89: 619-626.
45. Santambrogio L, Lipartiti M, Bruni A, Dal Toso R. Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol 1993; 45: 113-120.
46. Walker SE. Treatment of systemic lupus erythematosus with bromocriptine. Lupus 2001; 10: 197-202.